172 related articles for article (PubMed ID: 35058318)
1. Proceedings: PET Drugs-A Workshop on Inspections Management and Regulatory Considerations.
Bunning S; Ignace C; Mattmuller S; Schwarz SW; Scott PJH; VanBrocklin HF; Zigler SS;
J Nucl Med; 2022 Jul; 63(7):1117-1123. PubMed ID: 35058318
[TBL] [Abstract][Full Text] [Related]
2. Regulatory Requirements for PET Drug Production.
Schwarz SW; Dick D; VanBrocklin HF; Hoffman JM
J Nucl Med; 2014 Jul; 55(7):1132-7. PubMed ID: 24914057
[TBL] [Abstract][Full Text] [Related]
3. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
Harapanhalli RS
Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
[TBL] [Abstract][Full Text] [Related]
4. A rational regulatory approach for positron emission tomography imaging probes: from "first in man" to NDA approval and reimbursement.
Barrio JR; Marcus CS; Hung JC; Keppler JS
Mol Imaging Biol; 2004; 6(6):361-7. PubMed ID: 15564146
[TBL] [Abstract][Full Text] [Related]
5. Transforming an Academic Radiochemistry Facility for Positron Emission Tomography Drug cGMP Compliance.
Zhu S; Mosessian S; Kroeger K; Sadeghi S; Slavik R; Kinloch S; Moore M; Allen-Auerbach M; Czernin J; Phelps M
Mol Imaging Biol; 2020 Apr; 22(2):256-264. PubMed ID: 31240531
[TBL] [Abstract][Full Text] [Related]
6. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
Basile EM; Tolomeo D; Gluck E
Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
[TBL] [Abstract][Full Text] [Related]
7. Instrumentation and radiopharmaceutical validation.
Zigler SS
Q J Nucl Med Mol Imaging; 2009 Aug; 53(4):402-10. PubMed ID: 19834450
[TBL] [Abstract][Full Text] [Related]
8. Revocation of regulation on positron emission tomography drug products--FDA. Final rule; revocation.
Fed Regist; 1997 Dec; 62(244):66522. PubMed ID: 10179303
[TBL] [Abstract][Full Text] [Related]
9. Current good manufacturing practice for positron emission tomography drugs.
Food and Drug Administration, HHS
Fed Regist; 2009 Dec; 74(236):65409-36. PubMed ID: 20169678
[TBL] [Abstract][Full Text] [Related]
10. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
11. A Roundtable Discussion: Combination Products: Twice the Challenge?
Baird N; Binion SB; Cammack J; Paine SD; Gonzales R; Passut J; Weiner JB
Biomed Instrum Technol; 2015; 49(5):322-9. PubMed ID: 26443908
[TBL] [Abstract][Full Text] [Related]
12. Regulatory Agencies and PET/CT Imaging in the Clinic.
Herscovitch P
Curr Cardiol Rep; 2022 Oct; 24(10):1361-1371. PubMed ID: 35913674
[TBL] [Abstract][Full Text] [Related]
13. Bringing New PET drugs to clinical practice - a regulatory perspective.
Hung JC
Theranostics; 2013 Nov; 3(11):885-93. PubMed ID: 24312157
[TBL] [Abstract][Full Text] [Related]
14. Regulation of the compounding of positron emission tomography drugs.
Hung JC
Am J Health Syst Pharm; 2001 Jan; 58(2):134-9. PubMed ID: 11202536
[TBL] [Abstract][Full Text] [Related]
15. Operation of a radiopharmacy for a clinical trial.
Norenberg JP; Petry NA; Schwarz S
Semin Nucl Med; 2010 Sep; 40(5):347-56. PubMed ID: 20674594
[TBL] [Abstract][Full Text] [Related]
16.
Carlucci G; Ippisch R; Slavik R; Mishoe A; Blecha J; Zhu S
J Nucl Med; 2021 Feb; 62(2):149-155. PubMed ID: 33443068
[TBL] [Abstract][Full Text] [Related]
17. From the History of the Croatian Dermatovenereological Society - The Croatian Medical Association and an Overview of Important Information Regarding the Journal Acta Dermatovenerologica Croatica.
Dobrić I
Acta Dermatovenerol Croat; 2018 Dec; 26(4):344-348. PubMed ID: 30665489
[TBL] [Abstract][Full Text] [Related]
18. Efficacy considerations for U.S. Food and Drug Administration approval of diagnostic radiopharmaceuticals.
Gorovets A; Marzella L; Rieves D; Yang L
J Nucl Med; 2013 Aug; 54(8):1479-84. PubMed ID: 23749997
[TBL] [Abstract][Full Text] [Related]
19. [Regulatory Framework for Approval of PET Drug in Korea: A Survey Report].
Kurihara C; Inoue T
Kaku Igaku; 2015 Nov; 52(4):341-52. PubMed ID: 27263269
[TBL] [Abstract][Full Text] [Related]
20. Explanations and unresolved issues pertaining to the development of the Nuclear Pharmacy Compounding Guidelines.
Hung JC; Augustine SC; Cheng KT; Green RL; Hopkins WM; Laven DL; Nelson BR; Petry NA; Ponto JA; Quinton TM; Swanson DP
J Am Pharm Assoc (Wash); 2002; 42(5):789-98. PubMed ID: 12269713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
